Efficacy News and Research

RSS
Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Octapharma announces new study of IVIG in chronic inflammatory demyelinating polyradiculoneuropathy

Silence Therapeutics receives two patents for RNA interference therapeutics

Silence Therapeutics receives two patents for RNA interference therapeutics

Synthetic derivative of Retinoic acid can induce cell death

Synthetic derivative of Retinoic acid can induce cell death

Study finds multivitamins have no impact on cancer recurrence, survival

Study finds multivitamins have no impact on cancer recurrence, survival

Bariatric surgery before pregnancy reduces odds of developing gestational diabetes

Bariatric surgery before pregnancy reduces odds of developing gestational diabetes

Morning sickness treatment still elusive: Review

Morning sickness treatment still elusive: Review

Also in Global Health News: India's antibiotic use; Abstinence curriculum in China; Child, maternal health in India; Plumpy'nut; PEPFAR funds to Uganda

Also in Global Health News: India's antibiotic use; Abstinence curriculum in China; Child, maternal health in India; Plumpy'nut; PEPFAR funds to Uganda

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

Rexahn submits Phase IIb protocol to FDA for study of Serdaxin for major depressive disorder

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

CytRx commences PROACT Phase 2 clinical trial of bafetinib for advanced prostate cancer

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Promedior initiates PRM-151 Phase 2a clinical study in prevention of scarring post glaucoma filtration surgery

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Positive immune responses elicited from Scancell's DNA vaccine in combination with ImmuneRegen's Homspera

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

Idenix Pharmaceuticals receives clinical hold order from FDA for IDX184, IDX320 programs

GI Dynamics announces data on EndoBarrier therapy for type 2 diabetes, obesity

GI Dynamics announces data on EndoBarrier therapy for type 2 diabetes, obesity

RA synthetic derivative 4-HPR's ability to induce tumour cell death

RA synthetic derivative 4-HPR's ability to induce tumour cell death

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

Hallucinogen psilocybin safe for administration in patients with advanced-stage cancer and anxiety: Study

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

ImmunoCellular Therapeutics updates accomplishments in Letter to Shareholders

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

Celldex Therapeutics regains worldwide rights to commercialize rindopepimut therapeutic cancer vaccine

WHO revises treatment protocols for HIV patients

WHO revises treatment protocols for HIV patients

Data from ESC confirms reduction in adverse events with CYPHER Stent

Data from ESC confirms reduction in adverse events with CYPHER Stent

European Menopause and Andropause Society's position statements on post-reproductive health of women

European Menopause and Andropause Society's position statements on post-reproductive health of women

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.